
    
      The study is currently in the "expansion" phase after finding the recommended phase 2 dose in
      the dose/schedule escalation cohorts. Eighteen patients will be enrolled in the expansion
      phase. Vincristine is administered starting cycle 1, along with a 14 day continuous infusion
      of TK216.
    
  